Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Long-Term Deferred Tax (2016 - 2017)

GT Biopharma (GTBP) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $15.9 million as the latest value for Q4 2017.

  • On a quarterly basis, Long-Term Deferred Tax fell 25.65% to $15.9 million in Q4 2017 year-over-year; TTM through Dec 2017 was $15.9 million, a 25.65% decrease, with the full-year FY2017 number at $15.9 million, down 25.65% from a year prior.
  • Long-Term Deferred Tax was $15.9 million for Q4 2017 at GT Biopharma, down from $21.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $21.4 million in Q4 2016 to a low of $15.3 million in Q4 2014.
  • A 3-year average of $17.6 million and a median of $15.9 million in 2017 define the central range for Long-Term Deferred Tax.
  • Biggest YoY gain for Long-Term Deferred Tax was 25.65% in 2017; the steepest drop was 25.65% in 2017.
  • GT Biopharma's Long-Term Deferred Tax stood at $15.3 million in 2014, then soared by 39.81% to $21.4 million in 2016, then dropped by 25.65% to $15.9 million in 2017.
  • Per Business Quant, the three most recent readings for GTBP's Long-Term Deferred Tax are $15.9 million (Q4 2017), $21.4 million (Q4 2016), and $15.3 million (Q4 2014).